Genomic Vision Launches “GV STORE” Online Store to Support Sales of Product from LSR Activities

BAGNEUX, France--()--Regulatory News:

Genomic Vision (Paris:GV) (FR0011799907 – GV), a company specialized in the development of diagnostic solutions for the early detection of cancers and serious genetic diseases and tools for life sciences research, today announced it has launched a new commercial website, the GV Store, to enable its global client base to order products and services of LSR activities directly on-line.

“In order to address the high demand of our LSR solutions, in particular in international markets where we realize 90% of our sales, it was essential to propose our customers a simple and fast process of order taking and administrative follow. Thanks to GV Store we are extremely confident as for the long-lasting acceleration of our sales of products and services. While reducing delays of delivery, this e-commerce site comes to strengthen the added value of our technologies with life science research labs,” commented David Del Bourgo, Marketing and Sales Director of Genomic Vision.

Genomic Vision offers the Molecular Combing platform, a technology that enables the detection of structural variations in the genome and analyzes dynamics parameters such as DNA replication. The company sells equipment, reagents and services directly to clients in Europe, the US and through distributors in China. Genomic Vision’s clients vary from clinical and academics laboratories, to biotechnology and pharmaceutical companies.

ABOUT GENOMIC VISION

GENOMIC VISION is a company specialized in the development of diagnostic solutions for the early detection of cancers and serious genetic diseases and tools for life sciences research. Through the DNA Molecular Combing, a strong technology allowing to identify genetic abnormalities, GENOMIC VISION stimulates the R&D productivity of the pharmaceutical companies, the leaders of the diagnostic industry and the research labs.

The Company develops a robust portfolio of diagnostic tests (breast, ovarian and colorectal cancers, myopathies) and analysis tools (DNA replication, biomarkers discovery, gene editing quality control). Based near Paris, in Bagneux, the Company has approximately 60 employees. GENOMIC VISION is a public listed company listed in compartment C of Euronext’s regulated market in Paris (Euronext: GV - ISIN: FR0011799907). For further information, please visit www.genomicvision.com

Member of CAC® Mid & Small and CAC® All-Tradable indexes

FORWARD LOOKING STATEMENT

This press release contains implicitly or explicitly certain forward-looking statements concerning Genomic Vision and its business.

Such forward-looking statements are based on assumptions that Genomic Vision considers to be reasonable. However, there can be no assurance that such forward-looking statements will be verified, which statements are subject to numerous risks, including the risks set forth in the “Risk Factors” section in its Document de Reference filed with the French Autorité des Marchés Financiers (AMF) on March 28, 2017, under number R.17-009, available on the web site of Genomic Vision (www.genomicvision.com) and to the development of economic conditions, financial markets and the markets in which Genomic Vision operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Genomic Vision or not currently considered material by Genomic Vision. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of Genomic Vision to be materially different from such forward-looking statements.

This press release and the information contained herein do not constitute and should not be construed as an offer or an invitation to sell or subscribe, or the solicitation of any order or invitation to purchase or subscribe for Genomic Vision shares in any country. The distribution of this press release in certain countries may be a breach of applicable laws. The persons in possession of this press release must inquire about any local restrictions and comply with these restrictions.

Contacts

Genomic Vision
Aaron Bensimon, +33 1 49 08 07 50
Co-founder, Chairman & CEO
investisseurs@genomicvision.com
or
Milestones
Press Relations
Bruno Arabian, +33 1 83 62 34 84
barabian@milestones.fr
or
NewCap
Investor Relations
Dušan Orešanský / Emmanuel Huynh, +33 1 44 71 94 92
gv@newcap.eu

Contacts

Genomic Vision
Aaron Bensimon, +33 1 49 08 07 50
Co-founder, Chairman & CEO
investisseurs@genomicvision.com
or
Milestones
Press Relations
Bruno Arabian, +33 1 83 62 34 84
barabian@milestones.fr
or
NewCap
Investor Relations
Dušan Orešanský / Emmanuel Huynh, +33 1 44 71 94 92
gv@newcap.eu